Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT07210606

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07210606
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07210606. Randomized; double masking; primary purpose treatment. Start 2026-09-16 (actual); primary completion 2030-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment
Acronym
CSA-HF
Condition
Sleep Disordered Breathing
Condition
Able Bodied
Intervention (Drug)
Trazodone + positive airway pressure (PAP) therapy
Intervention (Drug)
Oxygen + positive airway pressure (PAP) therapy
Lead sponsor
VA Office of Research and Development (class: US federal agency)

Record details

Record id
cardio:ct-nct07210606
Content hash
f64b7ea855fb163b2ad2b10685630db5fc0d23594c400c7d44df35019c475b40